Preclinical Validation of AR42, a Novel Histone Deacetylase Inhibitor, as Treatment for Vestibular Schwannomas

Laryngoscope - United States
doi 10.1002/lary.22392
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Activity of PXD101, a Histone Deacetylase Inhibitor, in Preclinical Ovarian Cancer Studies

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Preclinical Anti-Arthritic Study and Pharmacokinetic Properties of a Potent Histone Deacetylase Inhibitor MPT0G009

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2014English

Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, With Chemotherapy for the Treatment of Soft Tissue Sarcoma

Clinical Cancer Research
Cancer ResearchOncology
2009English

Correction: Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, With Chemotherapy for the Treatment of Soft Tissue Sarcoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

Vestibular Schwannomas

Chettinad Health City Medical Journal
2015English

Epigenetic Modulation With Oral Histone Deacetylase (HDAC) Inhibitor as a New Treatment Option in JIA

Pediatric Rheumatology
ImmunologyPediatricsRheumatologyAllergyPerinatologyChild Health
2011English

Preclinical Studies on Histone Deacetylase Inhibitors as Therapeutic Reagents for Endometrial and Ovarian Cancers

Future Oncology
MedicineCancer ResearchOncology
2011English

A Novel Histone Deacetylase Inhibitor, CKD5, Has Potent Anti-Cancer Effects in Glioblastoma

Oncotarget
Oncology
2016English

Gamma Knife Radiosurgery for Treatment of Growing Vestibular Schwannomas in Patients With Neurofibromatosis Type 2: A Matched Cohort Study With Sporadic Vestibular Schwannomas

Journal of Neurosurgery
SurgeryNeurology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy